Arrayit, Sunnyvale, Calif, offers the market’s first service dedicated exclusively to elucidating orphan human diseases. These rare conditions present in a small percentage of the population, with one case typically occurring for every 1,000 to 200,000 persons. Arrayit deploys its patented, proprietary microarray platform on a genomic scale to rapidly elucidate an orphan disease’s molecular basis. Control and test samples of mRNA are compared to produce a gene expression signature for each condition, and gene expression data are computationally examined to produce a “best-fit” biological pathway. The sensitivity and specificity of the microarray platform enable a deeper examination of the transcriptome than many competing platforms and a more complete understanding of orphan diseases. The company also offers genotyping and proteomic analyses to confirm and extend each analysis. For more information, visit Arrayit.